Gilead Sciences (GILD) Amortizatization of Intangibles (2009 - 2026)
Gilead Sciences' (GILD) quarterly Amortizatization of Intangibles came in at $600.0 million in Q2 2026, little changed on a YoY basis from $598.0 million in Q2 2025, and up 0.67% quarter-over-quarter from $596.0 million in Q1 2026.
Analysis
Gilead Sciences (GILD) Amortizatization of Intangibles (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported Amortizatization of Intangibles for 18 consecutive years, with $600.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Amortizatization of Intangibles changed 0.33% year-over-year to $600.0 million; the trailing twelve-month figure through Jun 2026 stood at $2.4 billion (changed 0.08% YoY), and the FY2025 full-year result was $2.4 billion, changed 0.17% from the prior year.
- Amortizatization of Intangibles rose to $600.0 million in Q2 2026 per GILD's latest filing, from $596.0 million in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $600.0 million in Q2 2026 and bottomed at $445.0 million in Q1 2022.
- Historically, Amortizatization of Intangibles has averaged $560.6 million across 5 years, with a median of $596.0 million in 2024.
- The sharpest annual moves came in 2023 and 2026: Amortizatization of Intangibles jumped 34.38% in 2023, then declined 0.5% in 2026.
- Over 5 years, Amortizatization of Intangibles stood at $445.0 million in 2022, then soared by 34.16% to $597.0 million in 2023, then gained by 0.17% to $598.0 million in 2024, then fell by 0.17% to $597.0 million in 2025, then climbed by 0.5% to $600.0 million in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $600.0 million, $596.0 million, and $597.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 600.00 Mn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | - |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | - |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | 1.39 Mn |
| 10 | Insmed | 26.19 Bn | 25.03 Bn | 358.27 Mn | 678,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 600.00 Mn |
| Mar 31, 2026 | 596.00 Mn |
| Dec 31, 2025 | 597.00 Mn |
| Sep 30, 2025 | 596.00 Mn |
| Jun 30, 2025 | 598.00 Mn |
| Mar 31, 2025 | 599.00 Mn |
| Dec 31, 2024 | 598.00 Mn |
| Sep 30, 2024 | 596.00 Mn |
| Jun 30, 2024 | 596.00 Mn |
| Mar 31, 2024 | 596.00 Mn |
| Dec 31, 2023 | 597.00 Mn |
| Sep 30, 2023 | 598.00 Mn |
| Jun 30, 2023 | 598.00 Mn |
| Mar 31, 2023 | 546.00 Mn |
| Dec 31, 2022 | 445.00 Mn |
| Sep 30, 2022 | 445.00 Mn |
| Jun 30, 2022 | 445.00 Mn |
| Mar 31, 2022 | 445.00 Mn |
| Dec 31, 2021 | 445.00 Mn |
| Sep 30, 2021 | 441.00 Mn |